Why it was recalled
Subpotent Drug
Product description
Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy
Lot numbers, UPCs & expiration codes
03202025@9 BUD 07/18/2025
Where it was sold
U.S. Nationwide
What to do if you have this product
- Compare the lot number and expiration date on your package with the codes above.
- Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
- If you have symptoms you think are related, contact your doctor. In an emergency call 911.
- Report side effects to FDA MedWatch at 1-800-FDA-1088.
Recall details
- Recall number
- D-0608-2025
- Classification
- Class II
- Status
- Ongoing
- Recall initiated
- Jul 9, 2025
- FDA report date
- Sep 10, 2025
- Quantity
- 186 vials
- Recall type
- Voluntary: Firm initiated
- Recalling firm
- Boothwyn Pharmacy LLC
Original FDA data
Every field from FDA enforcement report D-0608-2025, exactly as published.
Show all FDA fields
- City
- Kennett Square
- State
- PA
- Status
- Ongoing
- Country
- United States
- Event ID
- 97202
- Address
- 221 Gale Ln
- Code information
- 03202025@9 BUD 07/18/2025
- Postal code
- 19348
- Report date
- Sep 10, 2025
- Product type
- Drugs
- Recall number
- D-0608-2025
- Classification
- Class II
- Recalling firm
- Boothwyn Pharmacy LLC
- Product quantity
- 186 vials
- Reason for recall
- Subpotent Drug
- Voluntary / mandated
- Voluntary: Firm initiated
- Product description
- Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy
- Distribution pattern
- U.S. Nationwide
- Recall initiation date
- Jul 9, 2025
- Initial firm notification
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
- Center classification date
- Aug 29, 2025